Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
The Oncologist|July 11, 2023
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)Mehmet A Bilen, Scott B Robinson, Amy Schroeder, et al.
Case Reports in Oncology|April 21, 2020
Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung AdenocarcinomaKaterina Zakka, Patrick Zakka, Amir Davarpanah, et al.
The Oncologist|August 12, 2025
Impact of Treatment Patterns and Sequencing on Clinical and Economic Outcomes in Patients with Metastatic Urothelial Cancer: IMPACT UC II StudyMehmet A Bilen, Brandon Diessner, John White, et al.
The Oncologist|July 31, 2024
Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancerMehmet A Bilen, Ibrahim Khilfeh, Carmine Rossi, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor ThrombusViraj A Master, Benjamin N Schmeusser, Adeboye O Osunkoya, et al.
Therapeutic Advances in Medical Oncology|May 25, 2026
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancerMehmet A Bilen, Benjamin H Lowentritt, Sabree Burbage, et al.
Future Oncology (London, England)|February 24, 2025
A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trialsPaul Leger, Stanley Frencher, Jones T Nauseef, et al.
Clinical Genitourinary Cancer|April 12, 2023
Identifying the Needs of Health Care Providers in Advanced First-Line Renal Cell Carcinoma: A Mixed-Methods ResearchPatrice Lazure, Matthew T Campbell, Monica Augustyniak, et al.
Advances in Therapy|May 29, 2025
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate CancerMehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Journal of Comparative Effectiveness Research|May 9, 2025
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USABenjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, et al.
Pageof 14